Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD4 | P21917 | 7/20 | 0.49 |
| ▸ | HTR1A | P08908 | 6/20 | 0.48 |
| ▸ | SLC6A4 | P31645 | 3/20 | 0.48 |
| ▸ | DRD2 | P14416 | 2/20 | 0.47 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.46 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.44 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL14571534 | 0.92 | HTR1A (0.49) | DRD4HTR1ASLC6A4DRD2KCNH2 | |
| SCHEMBL5584673 | 0.92 | HTR1A (0.51) | DRD4HTR1ASLC6A4DRD2KCNH2 | |
| SCHEMBL5585062 | 0.91 | HTR1A (0.48) | DRD4HTR1ASLC6A4DRD2KCNH2 | |
| SCHEMBL5584396 | 0.91 | DRD4 (0.51) | DRD4HTR1ASLC6A4DRD2KCNH2 | |
| SCHEMBL5584144 | 0.90 | HTR1A (0.48) | DRD4HTR1ASLC6A4DRD2KCNH2 | |
| SCHEMBL5584366 | 0.90 | HTR1A (0.48) | DRD4HTR1ASLC6A4DRD2KCNH2 | |
| SCHEMBL5584505 | 0.89 | DRD4 (0.46) | DRD4HTR1ASLC6A4DRD2KCNH2 | |
| SCHEMBL5584916 | 0.88 | HTR1A (0.47) | DRD4HTR1ASLC6A4DRD2KCNH2 | |
| SCHEMBL5584962 | 0.88 | ALDH1A1 (0.50) | DRD4HTR1ASLC6A4DRD2KCNH2 | |
| SCHEMBL5584680 | 0.88 | ALDH1A1 (0.50) | DRD4HTR1ASLC6A4DRD2KCNH2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-7196199-B2 | Antiserotonine agents; antidepressants | MITSUBISHI PHARMA CORPORATION (JP) | 2007-03-27 | — | — | US | disclosed |
| US-20040138227-A1 | Phenoxypropylamine compounds | NISHIYAMA AKIRA | 2004-07-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040138227-A1 | Phenoxypropylamine compounds | HTR1A, HTR1D, HTR5A | DRD4 42/4885HTR1A 1/4885SLC6A4 10/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.